0001209191-24-002942.txt : 20240206
0001209191-24-002942.hdr.sgml : 20240206
20240206191643
ACCESSION NUMBER: 0001209191-24-002942
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240202
FILED AS OF DATE: 20240206
DATE AS OF CHANGE: 20240206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morrell Martha
CENTRAL INDEX KEY: 0001855616
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40337
FILM NUMBER: 24601671
MAIL ADDRESS:
STREET 1: C/O NEUROPACE INC
STREET 2: 455 N. BERNARDO AVENUE
CITY: MOUTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NeuroPace Inc
CENTRAL INDEX KEY: 0001528287
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 223550230
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 N. BERNARDO AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 6502372700
MAIL ADDRESS:
STREET 1: 455 N. BERNARDO AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-02-02
0
0001528287
NeuroPace Inc
NPCE
0001855616
Morrell Martha
455 N. BERNARDO AVENUE
MOUNTAIN VIEW
CA
94043
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-02-02
4
S
0
14143
15.0691
D
81208
D
Common Stock
2024-02-05
4
S
0
3446
15.1707
D
77762
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.285, inclusive. The
reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
/s/ Irina Ridley, Attorney-In-Fact
2024-02-06